Clinical Trial Update: A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated elacytarabine (CP-4055) plus idarubicin as a second-course remission-induction therapy for acute myeloid leukemia. The study has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Elacytarabine
• Idarubicin (idarubicin)

Snippet

Sponsor: Clavis Pharma | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED